Physician profile
Samuel David Smith
NPI 1184346280
$4,423.58
in general payments reported to CMS, 2019-2025
22 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,321 · 2024: $1,780 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,151 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.16 |
| Education | $272.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.16 | 2023-2025 | |
| Janssen Biotech, INC. | $471.37 | 2023-2025 | Tremfya |
| Ucb, INC. | $461.59 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $442.27 | 2023-2024 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $406.22 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $320.56 | 2023-2025 | |
| Dermavant Sciences, INC. | $269.20 | 2023-2024 | Vtama |
| Incyte Corporation | $245.46 | 2023-2024 | Opzelura |
| Amgen INC. | $243.26 | 2023-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $188.84 | 2023-2024 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $181.58 | 2023-2024 | Aklief, Oracea, Epsolay |
| Sun Pharmaceutical Industries INC. | $138.21 | 2024 | |
| Arcutis Biotherapeutics, INC. | $133.25 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $118.89 | 2023-2024 | |
| Pfizer INC. | $64.91 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $54.80 | 2023 | |
| Journey Medical Corporation | $52.55 | 2023-2024 | |
| Biofrontera INC. | $43.03 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Kerecis Limited | $33.72 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Organon LLC | $19.63 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.37 | 2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.